RxDoctor Payments Data

Kaycie Langston

Family · Thomasville, GANPI 1457987349

Payments from drug & device makers

$5,095in general payments, 2019–2025

Across 304 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$767
  • Novo Nordisk$707
  • Boehringer Ingelheim$503
  • Bayer$502
  • Pfizer$465
  • Lilly USA, LLC$418
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,095100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,095 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$47,228
Medicare patients
244
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$67,035
MounjaroTirzepatide47$49,151
TrulicityDulaglutide36$44,425
FarxigaDapagliflozin Propanediol46$42,912
JardianceEmpagliflozin29$41,898
OzempicSemaglutide28$33,865
LinzessLinaclotide18$21,767
Tresiba Flextouch U-200Insulin Degludec32$18,371
RybelsusSemaglutide14$16,512
XareltoRivaroxaban19$15,936
UbrelvyUbrogepant12$13,637
EntrestoSacubitril/Valsartan14$12,888
Tresiba Flextouch U-100Insulin Degludec19$4,573
Atorvastatin Calcium190$1,694
Gabapentin73$1,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$418$93,57683 claims
PfizerEliquis$465$67,03593 claims
Novo NordiskOzempic, Rybelsus$707$50,37742 claims
AstraZenecaFarxiga$251$42,91246 claims
Boehringer IngelheimJardiance$503$41,89829 claims
AbbVieLinzess, Ubrelvy$767$35,40430 claims
Almatica Pharma LLCSertraline Hcl$18$26244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →